Tyndall Mark Anthony 4
4 · Keenova Therapeutics plc · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
Keenova EVP & CLO Mark Tyndall Receives 51,794 RSUs
What Happened
Mark Tyndall (EVP, Chief Legal Officer & Corporate Secretary) received a grant of 51,794 restricted stock units (RSUs) on Feb 25, 2026. The RSUs were granted at $0.00 per unit (award/derivative), meaning no cash was paid; each RSU will convert into one ordinary share upon vesting.
Key Details
- Transaction date: 2026-02-25; Form 4 filed 2026-02-26 (appears timely).
- Security and amount: 51,794 RSUs (derivative award) granted at $0.00.
- Vesting: RSUs will settle one-for-one into ordinary shares (F1). They vest ratably on each of the first three anniversaries of February 25, 2027 (F2).
- Shares owned after transaction: not disclosed in this filing.
- Filing note: This Form 4 also serves as notice to the issuer under Part V of the Companies Act 2014.
Context
RSU grants are a common form of executive compensation and are not purchases or sales of market shares; they typically incentivize retention and align executives with shareholder interests. Because these RSUs vest over time, they do not represent immediately tradeable shares at grant.
Insider Transaction Report
Form 4
Tyndall Mark Anthony
EVP & CLO and Corp Sec
Transactions
- Award
Restricted Stock Units
[F1][F2]2026-02-25+51,794→ 97,825 total→ Ordinary Shares (51,794 underlying)
Footnotes (2)
- [F1]Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
- [F2]The RSUs will vest ratably on each of the first three anniversaries of February 25, 2027.
Signature
/s/ Mark Tyndall|2026-02-26